Creating a model using patient samples for gastrointestinal cancer research
Official title: Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
Run by University of California, Irvine · NCT05844865 · Data updated 2026-11-12
This study is trying to create a model using samples from patients with gastrointestinal cancer to better understand the disease and find better treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of California, Irvine Academic / other |
| Locations | 1 site (Orange, California) |
| Status | Recruiting |
| Started | May 4, 2023 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | August 14, 2026 |
| Trial ID | NCT05844865 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have a gastrointestinal tumor and are scheduled for a standard surgical procedure.
✕Probably not a fit
Patients who are unable to comply with the study protocol or do not have a gastrointestinal tumor will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to collect and utilize samples from patients diagnosed with gastrointestinal peritoneal carcinomatosis. Participants will provide blood, ascites/peritoneal wash fluid, and tumor samples during their scheduled surgical procedures. The goal is to develop a patient-derived vascularized microtumor model that can help in understanding the disease better and potentially lead to improved treatment strategies.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of gastrointestinal peritoneal carcinomatosis and lead to more effective treatment options for patients.
How similar studies have gone: While this approach is innovative, similar studies utilizing patient-derived models have shown promise in other cancer types, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have a GI tumor * Must have planned standard of care surgical procedure * Age ≥ 18 years. * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: \- Pattens who are unable to comply with the study protocol
Where it's running
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, United States Recruiting
Study contacts
- Principal investigator: Maheswari Senthil, MD FACS — Chao Family Comprehensive Cancer Center
- Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
- Email: ucstudy@uci.edu
- Phone: 1-877-827-7883
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Repeated PIPAC plus standard platinum–taxane chemotherapy for advanced ovarian cancer with peritoneal spread
This test sees if adding repeated cisplatin-based PIPAC to standard platinum–taxane chemotherapy helps women aged 18–75 with newly diagnosed FIGO IIIB–IIIC epithelial ovarian cancer and visible peritoneal carcinomatosis.
-
Enhanced Recovery After Surgery for adults with peritoneal carcinomatosis undergoing cytoreductive surgery with or without HIPEC
This project will try an Enhanced Recovery After Surgery (ERAS) program to see if it shortens hospital stays after cytoreductive surgery with or without HIPEC for adults with peritoneal carcinomatosis.
-
PIPAC with Mitomycin C for unresectable peritoneal cancer
This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.
-
Heated versus aerosolized chemotherapy delivered into the abdomen for cancer that has spread to the peritoneum
This study will test whether heated (HIPEC) or aerosolized (PIPAC) mitomycin-based chemotherapy given into the abdomen works better and is safer for adults whose cancer has spread to the peritoneum.
-
Adding paclitaxel into the abdominal cavity for gastric cancer that has spread to the peritoneum
This trial will try adding paclitaxel delivered directly into the abdomen to standard IV chemotherapy for people with gastric or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity to see if it slows disease growth and helps them live longer.
-
Blood clearance of nucleosomes and CTCF after surgery for colorectal cancer with peritoneal spread
This test will see if blood levels of nucleosomes and CTCF can indicate whether adults with colorectal cancer that has spread to the peritoneum have had all visible tumor removed by cytoreductive surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.